For the first time in the federal NEC litigation, a jury is positioned to decide the merits of a bellwether case.
Closing arguments were completed Friday in Inman v. Mead Johnson & Company, ending a trial that put nearly every major issue driving MDL 3026 in front of a federal jury: general causation, specific causation, the comparative risk of formula and human milk, Mead Johnson's warnings, its involvement in the NICU marketplace and internal work involving possible alternative formulations of Enfamil Premature.
No reliable public account yet provides enough detail to accurately report the substance of José Rojas' or Mead Johnson's closing arguments. Rather than infer those arguments from the evidence, this Trial Intelligence Brief focuses on what the jury actually heard and the legal issues now positioned for decision.
One late development adds another layer. After all evidence was completed Friday, Mead Johnson renewed its motion for judgment as a matter of law under Rule 50(a), asking Judge Rebecca Pallmeyer to take both remaining claims away from the jury.
Mead Johnson specifically argues that testimony from defense expert Dr. Erika Claud left no legally sufficient basis for the jury to accept Alexis Inman's proposed lactose-based alternative formulation. Mead also renewed its earlier challenge to the failure-to-warn claim.
Judge Pallmeyer had previously rejected Mead Johnson's efforts to dispose of those claims before trial. Unless the court intervenes, the same issues Mead Johnson spent months trying to remove from the case are now positioned for decision by the first federal NEC jury.
For plaintiff lawyers following this litigation, that makes Inman considerably more than another infant-formula case. It is the first federal test of whether the NEC liability theories that survived Daubert, summary judgment and preemption challenges can survive a jury.
Daniel Windley's Medical Course
Understanding Inman begins with Daniel Windley's extraordinarily complicated medical history. Alexis Inman gave birth to twin boys, Daniel and Deyvon, on May 12, 2020, at Vidant Medical Center in Greenville, North Carolina. Daniel was born at 29 weeks gestation and weighed approximately 670 grams — about 1 pound, 7.6 ounces.
Pregnancy complications were substantial. Daniel suffered severe selective fetal growth restriction during a monochorionic-diamniotic twin pregnancy complicated by twin-to-twin transfusion syndrome. Maternal Rh alloimmunization caused severe fetal anemia, and Daniel required multiple blood transfusions before he was born and additional transfusions following delivery.
Those facts form a major part of Mead Johnson's defense. Nobody disputes that Daniel was an exceptionally vulnerable premature infant. Disagreement centers on what happened next.
A Feeding History That Became Central to the Case
Daniel's feeding history is unusually important because Inman is not simply a case about whether cow's-milk-based formula can increase NEC risk in premature infants. Plaintiff counsel also had to connect that risk to Daniel's actual feeding decisions. Daniel initially received human milk. As his nutritional needs evolved, physicians supplemented his feeds with cow's-milk-based fortifier.
Around two weeks after birth, doctors became concerned Daniel might suffer from galactosemia, a metabolic disorder affecting the body's ability to process galactose. Human milk was temporarily discontinued while that possibility was investigated, and Daniel received Nutramigen and Pregestimil, two hydrolyzed formulas.
Testing eventually ruled out galactosemia and human milk was resumed. A more significant change occurred during the following week. Enfamil Premature Formula was introduced around June 6. By June 11, Daniel's feeds had transitioned to Enfamil Premature without donor human milk. Seven days later, on June 18, his condition deteriorated. Daniel developed feeding intolerance, vomiting, respiratory instability and other symptoms. Imaging revealed pneumatosis intestinalis, one of the classic radiographic findings associated with NEC.
His disease progressed. Surgeons performed an exploratory laparotomy on June 22 and found extensive bowel injury. Daniel died the following day. That chronology became the factual bridge between the population-level science presented by plaintiff experts and their specific-causation theory involving Daniel.
Two Different Explanations for the Same Tragedy
Mead Johnson and Alexis Inman presented fundamentally different explanations for Daniel's NEC.
Mead Johnson's position begins with prematurity. Daniel was an extremely low-birth-weight infant with an extraordinarily complicated prenatal and neonatal history. Prematurity itself is a major risk factor for NEC, while severe fetal growth restriction, anemia, transfusions and the general instability associated with an infant born at 29 weeks all give Mead substantial causation evidence.
Plaintiff counsel does not have to prove those risks did not exist. Instead, Inman contends that exposure to Enfamil Premature materially increased Daniel's already significant NEC risk and ultimately contributed to the disease that killed him. That distinction has been one of the central scientific battles in the case. Mead Johnson says human milk may be protective without formula itself being causative. Inman says the difference cannot be dismissed as simply a protective benefit from human milk when epidemiological evidence shows materially different NEC outcomes depending on feeding exposure.
A jury must now determine what that evidence means in Daniel's particular case.
General Causation Survived the Federal Gatekeepers
Getting that question to a federal jury was not automatic. Earlier federal NEC bellwethers involving Abbott ended before trial after causation or case-specific evidence failed to survive the federal court's scrutiny. Inman followed a different path.
Plaintiff epidemiologist Dr. Logan Spector offered general-causation opinions concerning the relationship between cow's-milk-based formula and NEC in premature infants. His work involved a systematic review of epidemiological literature, including observational studies and randomized controlled trials, as well as application of the Bradford Hill criteria commonly used by epidemiologists when evaluating whether an observed association supports a causal inference.
Mead Johnson challenged his opinions under Rule 702 and argued, among other things, that Daniel's temporary exposure to hydrolyzed formulas made Spector's broader intact cow's-milk-protein analysis a poor fit for the case.
Judge Pallmeyer disagreed and allowed Spector to testify. That ruling did not mean she found his causation opinion correct. It meant his methodology and opinions cleared the federal evidentiary threshold and could be tested before a jury.
That distinction is important. Federal NEC plaintiffs had spent years fighting simply for the opportunity Inman has now reached.
Specific Causation: Dr. Chandani DeZure
General causation only gets the plaintiff halfway there. Someone still had to explain why Enfamil Premature contributed to Daniel Windley's NEC. Neonatologist Dr. Chandani DeZure filled that role. DeZure used a differential-etiology approach, examining Daniel's medical history, competing NEC risk factors, feeding exposures and the timing of his deterioration.
She ultimately attributed Daniel's NEC to his exposure to Enfamil Premature. Mead Johnson challenged her methodology as well, but Judge Pallmeyer allowed the testimony to reach the jury. Again, admissibility is not an endorsement of the conclusion. Jurors remain free to accept or reject DeZure's analysis. What matters for the broader MDL is that the specific-causation theory survived long enough to be tested in a federal courtroom.
Mead Johnson's Own Witness Acknowledged the Risk Difference
One of the more notable moments came late in the defense case. Mead Johnson's head of nutrition defended the safety of Enfamil Premature and testified that she had no reason to consider the product unsafe. At the same time, she acknowledged that premature infants receiving formula face a higher NEC risk than premature infants receiving human breast milk.
That distinction sits close to the heart of the case.
Mead Johnson can maintain that Enfamil is safe, nutritionally necessary and appropriate for premature infants while also recognizing the epidemiological difference between formula-fed and human-milk-fed populations. Plaintiff counsel asks the jury to look at that same difference from another direction: if the risk is materially different, what did Mead Johnson need to communicate to the neonatologists deciding what to feed premature babies? That question leads directly to Inman's warning claim.
This Is Not a Strict Liability Case
One legal distinction is particularly important for lawyers following Inman. North Carolina does not recognize strict tort liability in product-liability actions. Inman's surviving claims arise under the North Carolina Products Liability Act and are evaluated using negligence principles.
Two theories reached trial. First, Inman alleges Mead Johnson failed to provide adequate warnings concerning the NEC risk associated with Enfamil Premature. Second, she contends Mead Johnson acted unreasonably by failing to adopt a safer alternative formulation.
That legal framework matters because plaintiff counsel is not simply asking jurors to find that Enfamil was dangerous and impose liability. They must evaluate Mead Johnson's conduct: what the company knew, what information was reasonably available, what it communicated, whether safer alternatives were feasible and whether Mead Johnson acted reasonably under the circumstances. Those are negligence questions.
Failure to Warn May Be the Cleaner Liability Story
Among the surviving theories, failure to warn has always carried a particularly straightforward jury narrative. Physicians treating premature infants routinely make difficult risk-benefit decisions. A warning does not necessarily tell a doctor not to use a product; it provides information necessary to make that decision.
Inman contends Daniel's physicians were not given adequate information about the comparative NEC risk of Enfamil Premature. Mead Johnson answers that neonatologists already understood NEC, understood the advantages of human milk and independently made feeding decisions based on Daniel's nutritional and medical needs.
Judge Pallmeyer found enough evidence on both sides to make causation a jury question. Part of that evidence involves the environment in which those physicians received information about premature-infant nutrition.
"Own the NICU"
One of the more interesting corporate-conduct issues developed around what plaintiff counsel characterized as Mead Johnson's "own the NICU" strategy.
Inman presented evidence concerning Mead Johnson's efforts to maintain a strong presence in neonatal intensive care units at a time when donor human milk was becoming increasingly available. Company relationships with physicians, nutrition professionals and key opinion leaders became part of that story. Evidence also addressed Mead Johnson's relationship with Jennifer Fowler, who was involved in developing the feeding "Roadmap" used at Vidant.
Plaintiff counsel contends those relationships matter because manufacturers do more than put a label on a product. They communicate with hospitals, educate providers, promote products and participate in the broader medical-information environment in which feeding decisions are made.
Mead Johnson disputes the characterization that those activities improperly influenced Daniel's care. Its position is that his physicians exercised independent medical judgment and understood the available feeding options. Judge Pallmeyer did not decide which version was true. She decided there was enough evidence for jurors to decide.
The "Informational Vacuum"
Plaintiff briefing used another phrase that may ultimately become important to how lawyers view this trial: "informational vacuum."
Inman alleges Mead Johnson's communications contributed to an environment in which physicians understood the benefits of human milk but did not receive an adequate manufacturer warning identifying Enfamil's comparative NEC risk. Evidence included allegations concerning statements by Mead Johnson representatives about the nutritional consequences of relying too heavily on human milk. Mead Johnson disputes that those communications misled physicians.
Judge Pallmeyer was careful not to adopt the plaintiff's rhetoric as an established fact. What she did find was that the evidence created factual issues sufficient to survive summary judgment. Jurors now decide whether an informational problem actually existed and, if so, whether a different warning would have changed Daniel's feeding decisions.
Daniel's "Roadmap"
Vidant Medical Center's feeding protocol adds another layer. Evidence indicated that the NICU used a feeding "Roadmap" to guide nutritional decisions for premature infants. Donor human milk was preferred during certain stages, followed by transitions based on gestational age, growth and other clinical considerations.
Inman's theory links that protocol to Mead Johnson's influence within the NICU environment. Mead Johnson's answer is much simpler: hospital doctors developed and implemented Daniel's feeding plan. Those physicians—not Mead Johnson—decided when human milk should be supplemented or discontinued and when Enfamil Premature should be used.
That factual dispute gives the failure-to-warn claim unusual complexity. Warning causation does not exist in isolation. Jurors must consider whether a different warning from Mead Johnson would actually have reached Daniel's clinicians and changed what they did.
Alternative Design: Why Lactose Became Important
Inman's second surviving claim concerns formulation. Plaintiff evidence focused on whether Mead Johnson could have formulated Enfamil Premature differently, particularly by using lactose as the principal carbohydrate. Internal Mead Johnson work examining carbohydrate composition became relevant to that theory.
Researchers evaluated formulations and conducted studies that plaintiff counsel says show Mead Johnson was actively considering ways to influence NEC outcomes. Plaintiff experts contend a lactose-based formulation represented a feasible alternative that could have reduced NEC risk without destroying the usefulness of the product.
Mead Johnson strongly disputes that conclusion.
Animal research does not automatically translate to premature human infants. Possible research formulations are not necessarily commercially viable alternatives. Nutritional tolerance, regulatory requirements and the needs of extremely premature babies complicate any claim that a different carbohydrate formulation was simply available for adoption. That fight remained alive at the close of evidence.
Mead Johnson's Friday Rule 50 Motion
Friday's most important procedural development came after the evidence was completed. Mead Johnson renewed its request for judgment as a matter of law under Rule 50(a). In plain terms, Mead Johnson is asking Judge Pallmeyer to rule that even viewing the trial evidence in Inman's favor, no legally sufficient basis exists for the jury to find for her.
Both surviving claims are targeted. For the design claim, Mead Johnson points directly to testimony from Dr. Erika Claud. According to Mead's Friday filing, Claud testified that the medical and scientific community had already examined whether a purely lactose-based formula would be preferable for premature infants and found better feeding tolerance with lower-lactose rather than higher-lactose formulations.
Mead Johnson argues that testimony went unrebutted. North Carolina law requires a proposed alternative formulation to be safer and feasible without substantially impairing the product's usefulness, practicality or desirability. Mead's position is that Inman's proposed lactose formulation cannot satisfy that standard after Claud's testimony.
Failure to warn is also targeted. Rather than introduce an entirely new argument, Mead renewed the grounds it had raised earlier when seeking a directed verdict after the plaintiff rested. Judge Pallmeyer's handling of that motion is now another issue worth watching alongside the verdict.
Why Rule 50 Matters Even If the Jury Deliberates
Plaintiff lawyers should not treat the Rule 50 filing as unusual. Defendants routinely preserve these arguments in major trials. But it matters here because of the procedural history.
Mead Johnson unsuccessfully sought summary judgment before trial. It unsuccessfully challenged plaintiff experts. It raised a federal preemption argument shortly before trial, and Judge Pallmeyer rejected that effort without prejudice. Mead sought judgment after Inman rested and has now renewed the request after all evidence.
Each motion serves an immediate purpose and preserves arguments for potential post-verdict review. That means Inman could continue to generate important rulings even after the jury speaks.
Preemption Almost Stopped the Design Claim Before Trial
Another major pretrial fight involved federal regulation. Mead Johnson argued that Inman's alternative-design claim conflicted with the federal Infant Formula Act. Changing the formulation of a premature-infant product could trigger FDA notification requirements and regulatory scrutiny.
Mead argued that federal oversight effectively prevented state tort law from requiring the proposed alternative formulation. Judge Pallmeyer rejected that argument before trial. Her reasoning centered on an important distinction. FDA regulation of infant formula does not operate exactly like the premarket approval system governing certain other heavily regulated products. A requirement to notify FDA of a major formula change does not necessarily mean a manufacturer was legally prohibited from making that change. Possibility of an FDA objection, standing alone, was not enough to demonstrate impossibility. That ruling cleared one of the final obstacles keeping the alternative-design theory from the jury.
Earlier Federal Bellwethers Never Reached This Point
Context matters. Inman was the fourth case selected in the original federal bellwether wave. Earlier Abbott cases failed before juries could decide them. Expert issues, alternative-design problems and case-specific causation weaknesses prevented those cases from becoming the federal trial test MDL participants had expected.
Inman made it through. That makes it the first case in the federal NEC docket in which lawyers can evaluate not simply what Judge Pallmeyer thinks about admissibility or summary judgment, but what jurors think about the liability story. Bellwethers are intended to provide exactly that information.
One verdict will not mathematically determine the value of hundreds of other cases. Facts vary, medical histories vary, feeding records vary, treating physicians vary, and warnings and causation evidence vary. But a verdict finally gives both sides something federal NEC litigation has lacked: a jury data point.
Abbott's $670 Million Resolution Changes the Backdrop
Another major event occurred while Inman was moving toward the jury. Abbott agreed to approximately $670 million in payments resolving the Gill judgment and NEC claims involving roughly 2,000 additional infants. Calling that agreement a global NEC settlement would go too far. Thousands of claims remain outside the resolution, Abbott admitted no liability, and Mead Johnson is not part of the agreement. Still, its timing is difficult to ignore.
For years, NEC litigation has been fought largely through expert challenges, dispositive motions, state-court verdicts and appellate proceedings. Now one manufacturer has committed substantial money toward resolving a meaningful block of claims while another has taken the first federal bellwether through trial. Those are separate developments. Together, they make late August 2026 an important period in the evolution of the NEC litigation.
Why Watson Still Matters — But Only Up to a Point
Mead Johnson also entered Inman with a significant appellate victory from Illinois state court. A $60 million plaintiff verdict in Watson was reversed in June. Among the issues identified by the Illinois appellate court was the learned intermediary doctrine and the trial court's handling of the warning duty owed to treating physicians. That ruling matters strategically because it reinforces Mead Johnson's position that sophisticated medical professionals stand between the manufacturer and the patient.
But Watson does not decide Inman. Different state law applies. Daniel was treated in North Carolina, and North Carolina law governs Inman's substantive claims. Facts surrounding Daniel's physicians, the Vidant Roadmap and Mead Johnson's communications are also case-specific. So while Watson is part of the broader NEC landscape, the federal jury is deciding a different case under a different state's law.
Mead Johnson Has Real Defense Evidence
Plaintiff lawyers watching Inman should not underestimate the defense. Daniel's prematurity is not a peripheral fact. It is central. Born at 29 weeks and 670 grams after an extraordinarily complicated pregnancy, Daniel was already within the population at greatest risk for NEC. Mead Johnson can argue that plaintiff experts are taking an association between feeding exposure and NEC and converting it into proof of individual causation that the science cannot support. Doctors understood human milk was preferred when available. Doctors knew premature infants faced NEC risk. Doctors also understood that premature babies have demanding nutritional requirements that human milk alone does not always satisfy.
Daniel's physicians made those clinical decisions. Mead Johnson did not order his feeds. Those points give the defense multiple paths to a verdict.
Plaintiff's Answer Is About Information and Choice
Inman's strongest conceptual response may be that none of those defense facts eliminates the manufacturer's duty.
Doctors can understand NEC generally and still lack information a manufacturer should have provided about its particular product. A patient can have substantial baseline risk and still suffer an injury materially increased by another exposure. A hospital can make the ultimate feeding decision while relying on information supplied—or not supplied—by the manufacturer.
Those are the questions Judge Pallmeyer allowed this jury to consider. That is also why the trial has broader significance.
Federal NEC plaintiffs did not need to prove every premature infant fed cow's-milk-based formula will develop NEC. They needed a legally admissible path from the science, through a specific child's exposure, through Mead Johnson's conduct, to the injury claimed in the case. Inman became the first federal case to complete that path to trial.
José Rojas and the Plaintiff Trial Team
Lead trial counsel José Rojas reaches deliberations after helping develop the NEC litigation from its early stages. Rojas, a founding partner of Levin, Rojas, Camassar & Reck, became involved before the litigation was centralized in MDL 3026 and was later appointed Co-Lead Counsel. His background includes service in the Army Judge Advocate General's Corps, work as a Special Assistant United States Attorney and experience trying cases as a federal prosecutor before moving into plaintiff litigation.
Few mass-tort lawyers get the opportunity to take a liability theory from early case development through years of expert discovery and dispositive motions and ultimately put that case before a bellwether jury. Rojas has now done that.
Joining him is Diandra "Fu" Debrosse, who also serves as Co-Lead Counsel in the NEC litigation and brings extensive national mass-tort and product-liability leadership experience.
Je Yon Jung brings more than two decades of litigation experience, including earlier work with the U.S. Department of Justice Civil Rights Division and leadership roles in complex federal litigation.
Pearl Robertson has served on the Plaintiffs' Steering Committee and has worked extensively on the discovery and privilege issues underlying MDL 3026. Much of what jurors eventually see in a corporate product-liability trial begins years earlier with document discovery, privilege fights and internal corporate records. Robertson's role deserves recognition in that context.
Rojas' law partner Steven Reck also has a significant place in the history of this litigation. Reck filed the first case that helped develop what eventually became the nationwide NEC proceedings. Years later, a case from that litigation has finally reached a federal jury.
Friday Changed the Posture
Closing arguments were completed August 28. Reliable public reporting confirms both sides presented their final arguments and that jury deliberations were expected to begin Monday. Detailed public reporting on precisely what Rojas and Mead Johnson argued has remained limited. Atraxia Media will not attribute a closing theme, quote or argument to either side unless it can be verified. What can be said with certainty is that all evidence is complete, plaintiff and defense closings have been delivered, and Mead Johnson has renewed its Rule 50 motion.
For the first time, a federal NEC jury is being asked to decide the merits.
What the Jury's Decision Will and Will Not Tell Us
A plaintiff verdict would be important. It would demonstrate that an NEC case can survive federal expert scrutiny, survive summary judgment, survive preemption challenges and persuade a jury on the merits. That would matter to plaintiff lawyers evaluating similar cases. A defense verdict would matter just as much.
Mead Johnson would have a powerful argument that the first federal jury presented with a fully developed NEC case rejected liability despite hearing plaintiff epidemiology, specific-causation testimony, internal company evidence and the warning theories developed during years of MDL discovery. Neither outcome automatically determines the remaining docket.
Bellwethers are signals. Strong signals sometimes. But still signals. Case-specific medical histories and feeding records will continue to matter.
What We Are Watching Now
Three developments could come next. First, the jury. Any verdict becomes the most important federal NEC development since the creation of the MDL. Second, Judge Pallmeyer's Rule 50 ruling. Mead Johnson is asking the court to direct judgment on both claims. Whether the judge rules before or after a jury verdict may itself become important. Third, the verdict form. Judge Pallmeyer previously indicated that special verdict questions could be used to identify which causation theory supports any plaintiff verdict. That could matter enormously in post-trial motions and an eventual appeal.
After years of arguing about what a federal NEC jury might do, the litigation has finally reached the point where that question can be answered. The evidence is closed. The arguments are complete. The first federal NEC bellwether is now in the hands of the court and jury.
Atraxia Media is following Inman v. Mead Johnson and will report the verdict and any significant post-trial ruling as soon as they occur.